PODD · Insulet Corporation
$204.312026-05-17Sector: Healthcare; Industry: Medical - Devices; Sub-Industry: Health Care Equipment
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Base · active
$222
+8.9% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($141 · $300) Analysts Range ($286 · $435) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2021.Q4 | $1.1B | — | 15.1% | 15.1% | $140MM | −$408MM | −$267MM | 10.0% | — | 9.9% | $1.4B | $0.24 | — |
| 2022.Q4 | $1.3B | 18.8% | 3.8% | 45.0% | $27MM | −$211MM | −$184MM | 10.4% | — | 1.8% | $1.6B | $0.07 | — |
| 2023.Q4 | $1.7B | 30.0% | 17.0% | 3.9% | $278MM | −$297MM | −$20MM | 10.1% | — | 15.6% | $1.9B | $2.92 | — |
| 2024.Q4 | $2.1B | 22.1% | 19.6% | 0.0% | $565MM | −$173MM | $392MM | 10.8% | — | 27.7% | $2.2B | $5.92 | — |
| 2025.Q4 | $2.7B | 30.7% | 23.0% | 27.2% | $453MM | −$274MM | $179MM | 10.8% | — | 19.4% | $2.5B | $3.50 | 23.2 |
| italics below = DCF projection · 10yr Rev CAGR: 12.3% |
| 2026.Q4 | $3.3B | +22.3% | 23.1% | 26.5% | $563MM | −$579MM | −$17MM | 9.4% | −$15MM | 20.1% | $3.1B | $6.06 | 33.7 |
| 2027.Q4 | $4.0B | +19.5% | 24.8% | 25.8% | $729MM | −$645MM | $84MM | 9.3% | $70MM | 21.4% | $3.7B | $7.86 | 26.0 |
| 2028.Q4 | $4.7B | +18.8% | 27.5% | 25.0% | $969MM | −$772MM | $198MM | 9.3% | $151MM | 23.6% | $4.5B | $10.45 | 19.6 |
| 2029.Q4 | $5.5B | +17.3% | 28.9% | 24.3% | $1.2B | −$878MM | $328MM | 9.2% | $229MM | 24.4% | $5.4B | $12.99 | 15.7 |
| 2030.Q4 | $6.1B | +11.3% | 28.9% | 23.6% | $1.4B | −$704MM | $650MM | 9.1% | $418MM | 23.6% | $6.1B | $14.60 | 14.0 |
|
| Term. Yr+ | $9.0B | 4.1% | 23.3% | 20.0% | $1.7B | −$369MM | $1.3B | 8.6% | $12.1B | 18.5% | — | — | — |
Active scenario IV: $222 (+8.9% vs market)